Gene&autism: Study of the Genetic Factors Involved in Autism and Related Disorders

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France (Other)

Overall Status

Recruiting

CT.gov ID

NCT04727489

Collaborator

(none)

3,800

Enrollment

Locations

201.1

Anticipated Duration (Months)

633.3

Patients Per Site

3.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main objective of the study is to define, for Autism Spectrum Disorder, the extent of genetic variation in synaptic pathways that may be targeted for therapeutic development. For this purpose the investigators will take advantage of large, well-characterized cohorts of patients with Autism Spectrum Disorder for genetic screenings. Targeted sequencing of selected synaptic genes, previously associated with Autism Spectrum Disorder, will be carried out in these cohorts with deep coverage of coding regions and a strong focus on previously untested regulatory regions. Genomic data from Copy Number Variant, whole genome sequencing and exome sequencing, available for some of these patients, will be integrated in the overall analysis. The investigators will strongly emphasize the establishment of comprehensive genotype/phenotype correlations.

Condition or Disease	Intervention/Treatment	Phase
Autism Spectrum Disorder	Genetic: DNA from subjects will be stored in the biobank of our study.

Detailed Description

Aim 1: To identify genetic variants in selected synaptic genes, by targeted sequencing with deep coverage of coding regions and a strong focus on previously untested regulatory regions in Autism Spectrum Disorder

Aim 2: To define the range of clinical phenotypes caused by mutations in synaptic genes by establishing detailed genotype/phenotype correlations and analyzing segregation in families with multiple individuals affected by Autism Spectrum Disorder, Autism Spectrum Disorder traits or other neuropsychiatric disorders

Aim 3: To identify the neuronal phenotypes caused by deleterious synaptic mutations for further translational studies

Study Design

Study Type:

Observational

Anticipated Enrollment :

3800 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Study of the Genetic Factors Involved in Autism and Related Disorders

Actual Study Start Date :

Mar 30, 2021

Anticipated Primary Completion Date :

Dec 21, 2022

Anticipated Study Completion Date :

Dec 31, 2037

Arms and Interventions

Arm	Intervention/Treatment
Autism Spectrum Disorder Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.	Genetic: DNA from subjects will be stored in the biobank of our study. Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Other Names: diagnostic test
Control without Autism Spectrum Disorder Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).	Genetic: DNA from subjects will be stored in the biobank of our study. Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Other Names: diagnostic test
Relatives of probands with Autism Spectrum Disorder Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives) Without Autism Spectrum Disorder diagnosis according to DSM-V, With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders	Genetic: DNA from subjects will be stored in the biobank of our study. Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Other Names: diagnostic test
Relatives of controls Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives	Genetic: DNA from subjects will be stored in the biobank of our study. Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Other Names: diagnostic test

Outcome Measures

Primary Outcome Measures

Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder [up to 12 months after completion of the inclusion and molecular explorations]
Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder

Secondary Outcome Measures

Prevalence of the deleterious mutations in the major biological pathways in Autism Spectrum Disorder [up to 12 months after completion of the inclusion and molecular explorations]
The deleterious mutations that the investigators will identify in genes related to Autism Spectrum Disorders will help to have a comprehensive framework of biological pathways involved in Autism Spectrum Disorder

Eligibility Criteria

Criteria

Ages Eligible for Study:

24 Months to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria-----------------------------------------------------------------------------------

Probands with Autism Spectrum Disorder

Meet the diagnostic criteria for ASD of the DSM-5 [American Psychiatric Association, 2013] based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Rutter et al, 2003) and those of the Autism Diagnosis Observation Schedule (ADOS-2) (Lord et al, 2012)
Be at least 24 months (no upper age limit)
Somatic and Intellectual state compatible with a blood test
Affiliation to the social insurance
Signature of informed consent by the applicant or by holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship

Controls without ASD

At least 24 months old
Somatic and Intellectual state compatible with a blood test
Affiliation to the social insurance
Signature of informed consent by the subject or by holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship

Relatives of the probands with ASD or of controls without ASD

At least 24 months old
Somatic and Intellectual state compatible with a blood test
Affiliation to the social insurance
Signature of informed consent by the subject or by holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship

Exclusion Criteria

Probands with Autism Spectrum Disorder

Severe Intelectual Deficiency (IQ,35 or developmental age <18 months)

●. Personal psychiatric history (schizophrenia, bipolar disorder, substance use disorder (except tobacco), recurrent depression disorder, severe instable anxiety disorder)

Personal neurologic history (epilepsy, or severe neurological disease)

Relatives of the probands with ASD, of the controls or the controls:

● Medical condition (psychiatric or somatic) not compatible with the inclusion

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Albert Chenevier Hospital	Creteil	Ile De France	France	94000
2	Robert Debré Hospital	Paris	Ile De France	France	75019
3	CIC, CHU Bordeaux	Bordeaux		France
4	CRA, Hopital Charles Perrens, Bordeaux	Bordeaux		France
5	CIC, H. Mondor, Creteil	Créteil		France
6	Centre de rehabilitation psychosociale, Hopital Saint Egreve	Grenoble		France